Literature DB >> 15099971

The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.

Kelly L Molpus1, Lynne B Anderson, Carin L Craig, Joel G Puleo.   

Abstract

OBJECTIVE: The purpose of this study is to determine if regional cooling reduces palmar-plantar erythrodysesthesia (PPE) associated with intravenous infusion of pegylated liposomal doxorubicin (PLD).
METHODS: A retrospective review over 3 years identified 20 women who were treated with single-agent intravenous PLD for recurrent ovarian carcinoma. During PLD infusion, patients kept ice packs around their wrists and ankles, and consumed iced liquids. These steps were continued for 24 h after completion of chemotherapy. All patients were instructed not to ingest hot food or liquids, to avoid contact with hot water, and to minimize friction on the hands and feet for 72 h posttreatment.
RESULTS: Seventeen of the twenty patients (85%) followed the regional cooling protocol, and three of twenty (15%) did not. In the group who underwent regional cooling, 16/17 (94%) had none to mild PPE (grades 0-2), and 1/17 (6%) had moderate to severe PPE (grades 3-4). Of the three patients without regional cooling, 1/3 (33%) had grades 0-2 PPE and 2/3 (67%) had grades 3-4 PPE (P = 0.047).
CONCLUSIONS: Regional cooling may reduce the frequency and severity of PPE associated with intravenous PLD infusion for recurrent ovarian carcinoma. Prospective, randomized evaluation is needed to confirm this observation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099971     DOI: 10.1016/j.ygyno.2004.02.019

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.

Authors:  Justin M Julius; Janos L Tanyi; Graciela M Nogueras-Gonzalez; Jack L Watkins; Robert L Coleman; Judith K Wolf; Judith A Smith
Journal:  Int J Gynecol Cancer       Date:  2013-02       Impact factor: 3.437

2.  Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.

Authors:  Demet Cicek; Basak Kandi; Ferda A Dagli; Aziz Karaoglu; Beyzan D Haligur
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

3.  Pegylated liposomal doxorubicin in the management of ovarian cancer.

Authors:  Gabriella Ferrandina; Giacomo Corrado; Angelo Licameli; Domenica Lorusso; Gilda Fuoco; Salvatore Pisconti; Giovanni Scambia
Journal:  Ther Clin Risk Manag       Date:  2010-10-05       Impact factor: 2.423

4.  Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.

Authors:  Seiko Bun; Mayu Yunokawa; Yoshiko Tamaki; Akihiko Shimomura; Tatsunori Shimoi; Makoto Kodaira; Chikako Shimizu; Kan Yonemori; Yasuhiro Fujiwara; Yoshinori Makino; Hiroyuki Terakado; Kenji Tamura
Journal:  Support Care Cancer       Date:  2018-01-25       Impact factor: 3.603

5.  Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study.

Authors:  Mark Hackbarth; Norbert Haas; Christina Fotopoulou; Werner Lichtenegger; Jalid Sehouli
Journal:  Support Care Cancer       Date:  2007-08-07       Impact factor: 3.603

6.  Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients.

Authors:  Yan-Fu Zheng; Xin Fu; Xiao-Xu Wang; Xiao-Jing Sun; Xiao-Dan He
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

7.  Pegylated liposomal doxorubicin in ovarian cancer.

Authors:  Robert Strother; Daniela Matei
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

Review 8.  Dermatologic conditions in women receiving systemic cancer therapy.

Authors:  Michelle N Ferreira; Julie Y Ramseier; Jonathan S Leventhal
Journal:  Int J Womens Dermatol       Date:  2019-11-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.